



Certificate of Participation 2022

This is to certify that

Cogentech Srl Società Benefit

Participated in 2022 in the following EMQN CIC external quality assessment schemes:

Scheme	Genotyping	Interpretation	Clerical	Result
DNA SEQUENCING - NGS (Somatic - no matched germline sample)	2.00			Satisfactory
Hereditary Cancer (ILC)	2.00			Satisfactory
LYNCH	2.00	1.83	2.00	Satisfactory
OVARIAN and PROSTATE CANCER (v Somatic) [PARPi]	2.00	2.00	2.00	Satisfactory
OVARIAN, BREAST, PROSTATE and PANCREATIC CANCERS (v Germline) [PARPi]	2.00	2.00	2.00	Satisfactory
Polyposis Syndromes (FAP, MAP)	2.00	2.00	2.00	Satisfactory

The laboratory participated in 6 schemes and passed 6 of them. The detailed performance data are given on the Individual Laboratory Report (ILR). When viewing the certificates, you should ensure that 6 schemes are listed.

Key:

> Scheme Mean

< Scheme Mean

Poor performance

NRS: No Results Submitted **WFS:** Withdrew From Scheme

Signed by:



Prof. David Barton
Chair of SSAB



Dr. Simon Patton
Managing Director